DISCUSSION
coronavirus disease 2019
CORONAVIRUS DISEASE 2019
The potential of [The results showed that immunohistochemistry staining did not always reflect the biologic availability of the receptors; a HER2-positive biopsy sample with low [We found an inverse association between the number of previous treatments and the metabolic response to current treatment. The more treatments previously received, the higher the [Predicting positive metabolic response to HER2-targeted therapy in lymph nodes and soft-tissue lesions was possible using a prespecified cutoff SUVThe ability of [This study was initially intended as a multicentric phase II and phase III study, and the current data are the results from a prespecified interim analysis after inclusion of 40 patients. Unfortunately, the coronavirus disease 2019 pandemic coincided with the study, delaying our inclusion rate and prohibiting wider inclusion. In effect, intersite reproducibility remains to be studied. As we could not show a significant association between biopsy results and PET, which was the main endpoint, the planned phase III trial was aborted. Instead, further trials should focus on changes in clinical management and outcome using HER2 imaging.